BIOLASE, Inc.
BIOLNASDAQHealthcare
$0.02
+$0.00(+27.39%)
Market Cap$731942
P/E Ratio—
52W High$1.94
52W Low$0.0157
BIOLASE, Inc. (BIOL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BIOL · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $49.16M | $48.46M | $39.19M | $22.78M | $37.80M |
| Cost of Revenue | $32.44M | $32.55M | $22.66M | $16.61M | $23.51M |
| Gross Profit | $16.72M | $15.91M | $16.53M | $6.17M | $14.29M |
| Gross Margin %(computed) | 34.02% | 32.83% | 42.18% | 27.10% | 37.80% |
| Operating Expenses | |||||
| R&D Expenses | $6.00M | $7.26M | $6.05M | $3.69M | $4.76M |
| G&A Expenses | $10.22M | $12.31M | $11.26M | $9.77M | $10.75M |
| Total Operating Expenses | $34.66M | $41.25M | $32.65M | $24.71M | $29.91M |
| Operating Income | ($17.94M) | ($25.34M) | ($16.12M) | ($18.54M) | ($15.62M) |
| Operating Margin %(computed) | -36.48% | -52.28% | -41.12% | -81.37% | -41.33% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $2.36M | $2.75M | $2.22M | $2.36M | $2.16M |
| Income Before Tax | ($20.60M) | ($28.52M) | ($16.09M) | ($16.70M) | ($17.90M) |
| Income Tax Expense | $0.03M | $0.11M | $0.07M | $0.13M | ($0.04M) |
| Net Income | ($20.63M) | ($28.63M) | ($16.16M) | ($16.83M) | ($17.86M) |
| Net Margin %(computed) | -41.97% | -59.09% | -41.23% | -73.88% | -47.24% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-16.14 | $-413.19 | $-273.41 | $-688.19 | $-1923.95 |
| Wtd Avg Shares | 1.28M | 0.07M | 0.06M | 0.02M | 0.01M |
| EBITDA | ($15.44M) | ($25.28M) | ($13.47M) | ($13.84M) | ($14.76M) |
| EBITDA Margin %(computed) | -31.41% | -52.16% | -34.37% | -60.77% | -39.05% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more BIOLASE, Inc. data
About BIOLASE, Inc. (BIOL) Income Statement
BIOLASE, Inc. (BIOL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, BIOL reported revenue of $0.05B, gross profit of $0.02B (gross margin 34.02%), and net income of ($0.02B) — a net profit margin of -41.97%.
Frequently asked questions
BIOL · 4 questionsBIOLASE, Inc. (BIOL) reported revenue of $0.05B for 2023, up 1.4% year-over-year.
BIOL revenueBIOL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09